Drug Approval | September 01, 2021
Zymo Research receives CE Mark for new Covid-19 SafeCollect kits
Self-collection devices designed for ease of use and safety
Self-collection devices designed for ease of use and safety
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
Subscribe To Our Newsletter & Stay Updated
